CEO Olav Hellebø to leave Clavis Pharma

CEO Olav Hellebø to leave Clavis Pharma

Oslo, Norway, 14 May 2013

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that Olav Hellebø will leave the position as CEO of the company effective 20 May by mutual agreement.  This is a consequence of the significant down scaling of the Company's operations following the negative outcome of the CLAVELA phase III study in April.

Olav Hellebø said: "During my three years as CEO, Clavis Pharma has advanced two drug candidates through pivotal clinical trials. This is a significant undertaking for a small biotech company and it would not have possible without a very competent team and the support of our board and investors. We of course wished that the outcome of the studies was different.  I thank everyone involved and wish them the best of luck with their new ventures going forward."

Anders Wiklund, Chairman of the Board of Directors, said: "Olav has been an outstanding manager of the Clavis Pharma team. His enthusiasm and professionalism has created respect among all stakeholders of the company. On behalf of the Board, I would like to thank him for his excellent leadership and wish him well with his future endeavours."

Contacts:

Anders P. Wiklund

Chairman of the Board, Clavis Pharma ASA

+47 24 11 09 50

Mark Swallow / Nina Enegren / David Dible

Citigate Dewe Rogerson

+44 207 282 2948

[email protected]

Mark Swallow, Ph.D.

Citigate Dewe Rogerson

+44 (0)20 7282 2948 (direct)
+44 (0)7903 737703 (mobile)
+44 (0)20 7638 9571 (switchboard)
+44 (0)20 7282 2811 (fax)

3 London Wall Buildings
London Wall
London EC2M 5SY
UK

www.citigatedr.co.uk

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.